Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19333265 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | September 2025 | March 2026 | Allow | 6 | 1 | 0 | No | No |
| 19278342 | IL-23 ANTIBODY COMPOSITIONS AND METHODS OF USE | July 2025 | December 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19267411 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | July 2025 | August 2025 | Allow | 1 | 0 | 0 | No | No |
| 19252926 | BCMA x CD3 T BISPECIFIC CELL ENGAGER | June 2025 | December 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19229610 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS | June 2025 | October 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19209867 | ANTI-CD8 ALPHA DEPLETING ANTIBODIES | May 2025 | September 2025 | Allow | 4 | 0 | 1 | Yes | No |
| 19194993 | ALLOGENEIC HUMAN PLASMA AND PLATELET DERIVED PRODUCTS AND USES THEREOF | April 2025 | December 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 19192233 | Oral Dosing of GLP-1 Compounds | April 2025 | November 2025 | Allow | 6 | 1 | 0 | No | No |
| 19088722 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | March 2025 | September 2025 | Allow | 6 | 1 | 0 | No | No |
| 19088718 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | March 2025 | September 2025 | Allow | 6 | 1 | 0 | No | No |
| 19088729 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | March 2025 | November 2025 | Allow | 8 | 1 | 0 | No | No |
| 19087398 | HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS | March 2025 | August 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19079771 | PROTEIN-ENCLOSING POLYMERIC MICELLE | March 2025 | February 2026 | Allow | 11 | 1 | 0 | No | No |
| 19067426 | SELF-ASSEMBLING NANOPARTICLES | February 2025 | January 2026 | Allow | 11 | 1 | 1 | Yes | No |
| 19064136 | METHODS FOR THE TREATMENT OF MELANOMA USING COMPOSITIONS OF DENOSUMAB AND PD-1 INHIBITOR | February 2025 | December 2025 | Allow | 10 | 2 | 0 | Yes | No |
| 19062335 | MULTI-DOSE PEN OF TIRZEPATIDE | February 2025 | December 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 19061831 | METHODS OF TREATING INFLAMMATORY ARTHRITIS USING IL-17 ANTAGONISTS | February 2025 | January 2026 | Allow | 11 | 2 | 1 | Yes | No |
| 19058528 | COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASS | February 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19056312 | PD1 AND VEGFR2 DUAL-BINDING AGENTS | February 2025 | October 2025 | Allow | 8 | 1 | 1 | No | No |
| 19041480 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | January 2025 | August 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19037555 | MAMMALIAN CELL POPULATION AND MEDICAMENTS FOR CELL THERAPIES IN HUMANS AND IMPROVED CELL CULTIVATION METHODS | January 2025 | January 2026 | Allow | 11 | 1 | 0 | Yes | No |
| 19032762 | COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASS | January 2025 | January 2026 | Allow | 12 | 2 | 1 | Yes | No |
| 19017195 | ANTI-CD40 SINGLE-DOMAIN ANTIBODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF | January 2025 | January 2026 | Allow | 13 | 1 | 1 | No | No |
| 18881999 | ANTIBODY, NUCLEIC ACID, CELL, AND PHARMACEUTICAL | January 2025 | February 2026 | Allow | 13 | 1 | 1 | Yes | No |
| 18989629 | ZIP12 ANTIBODY | December 2024 | July 2025 | Allow | 6 | 0 | 1 | No | No |
| 18983037 | METHODS OF TREATING PSORIASIS WITH SECUKINUMAB | December 2024 | December 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18983034 | METHODS OF TREATING PSORIASIS WITH SECUKINUMAB | December 2024 | December 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18983030 | METHODS OF TREATING CHRONIC INFLAMMATORY DISEASE WITH SECUKINUMAB | December 2024 | December 2025 | Allow | 12 | 2 | 1 | Yes | No |
| 18982853 | PHOSPHORYLATED ANTIGEN AND ANTIBODY AT SER23 SITE OF PGAM1 PROTEIN AS WELL AS PREPARATION METHODS AND APPLICATIONS | December 2024 | August 2025 | Allow | 8 | 2 | 1 | Yes | No |
| 18979068 | METHODS FOR TREATING ALZHEIMER'S DISEASE USING SEMAGLUTIDE | December 2024 | September 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18967259 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | December 2024 | June 2025 | Allow | 7 | 2 | 1 | No | No |
| 18870747 | HYDROLYZED COLLAGEN FOR USE IN REDUCING BLOOD GLUCOSE | December 2024 | January 2026 | Allow | 13 | 1 | 1 | Yes | No |
| 18955328 | ANTI-TUMOR PHARMACEUTICAL COMPOSITION BASED ON IMMUNE CHECKPOINT BLOCKADE AND USE THEREOF | November 2024 | January 2026 | Allow | 14 | 3 | 1 | Yes | No |
| 18953973 | ACTRII PROTEINS AND USE IN TREATING POST-CAPILLARY PULMONARY HYPERTENSION | November 2024 | July 2025 | Allow | 8 | 2 | 0 | No | No |
| 18948648 | INTERLEUKIN 18 (IL-18) VARIANTS AND FUSION PROTEINS COMPRISING SAME | November 2024 | March 2025 | Allow | 4 | 0 | 1 | Yes | No |
| 18941441 | INTERLEUKIN-18 VARIANTS AND METHODS OF USE | November 2024 | December 2025 | Allow | 13 | 2 | 2 | Yes | No |
| 18861616 | COLLAGEN HYDROLYSATE COMPOSITION FOR REDUCING JOINT PAIN AFTER EXERCISE | October 2024 | June 2025 | Allow | 7 | 0 | 0 | Yes | No |
| 18861520 | HYDROGEL COMPOSITION, METHOD FOR PRODUCING THE SAME, AND USE THEREOF FOR STEM CELL MIMETIC PEPTIDE SUPPLEMENTATION | October 2024 | January 2026 | Abandon | 32 | 1 | 1 | No | No |
| 18929081 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | October 2024 | September 2025 | Allow | 11 | 2 | 0 | Yes | No |
| 18929510 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | October 2024 | February 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18927301 | PHARMACEUTICAL COMPOSITIONS COMPRISING COLLAGENASE I and COLLAGENASE II | October 2024 | December 2024 | Allow | 2 | 0 | 0 | No | No |
| 18859969 | TARGETED ANTI-SGLT1 AVIAN IGY ANTIBODIES AS TREATMENT OF PRE-DIABETES, TYPE 2 DIABETES AND GESTATIONAL DIABETES | October 2024 | November 2025 | Allow | 13 | 1 | 1 | No | No |
| 18914010 | CHIMERIC PROTEIN COMPRISING AN ANTI-INFLUENZA VIRUS ANTIBODY MOIETY AND A MUCOADHESIVE PEPTIDE FRAGMENT FOR PREVENTING OR TREATING INFLUENZA INFECTIONS | October 2024 | September 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18909225 | METHODS OF TREATING OR PREVENTING A CARDIOVASCULAR SYSTEM COMPLICATION OF SICKLE CELL DISEASE WITH AN ANTI-G-CSFR ANTIBODY | October 2024 | April 2025 | Allow | 7 | 1 | 1 | No | No |
| 18907424 | VASOPRESSIN PREMIX SYSTEMS AND USES THEREOF | October 2024 | July 2025 | Allow | 10 | 1 | 1 | No | No |
| 18901182 | ANTIBODY TARGETING B CELL MATURATION ANTIGEN AND RELATED PRODUCTS THEREOF AND MEDICAL APPLICATIONS | September 2024 | May 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18896718 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS | September 2024 | April 2025 | Allow | 7 | 2 | 1 | Yes | No |
| 18896286 | IL-15-BASED FUSIONS TO IL-12 AND IL-18 | September 2024 | December 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18889097 | Insulin Derivative | September 2024 | October 2025 | Abandon | 13 | 1 | 1 | Yes | No |
| 18883787 | METHOD OF MODIFYING ISOELECTRIC POINT OF ANTIBODY VIA AMINO ACID SUBSTITUTION IN CDR | September 2024 | November 2025 | Abandon | 14 | 2 | 0 | Yes | No |
| 18830877 | ANTI IL-6 DOMAIN ANTIBODIES WITH FATTY ACID SUBSTITUENTS | September 2024 | April 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18828243 | EARLY INTERVENTION METHODS TO PREVENT OR AMELIORATE TOXICITY | September 2024 | March 2025 | Allow | 6 | 2 | 0 | No | No |
| 18823573 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | September 2024 | January 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18821708 | METHODS OF CROSSLINKING IgG | August 2024 | May 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18817109 | ANTI-IL-18BP ANTIBODIES | August 2024 | April 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18808126 | ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) METHOD AND MONOCLONAL ANTIBODY FOR GIANT PANDA RELAXIN-3 (RLN3) | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18807825 | APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18804738 | INTERLEUKIN 21 VARIANTS | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18792080 | HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION | August 2024 | May 2025 | Abandon | 9 | 1 | 0 | Yes | No |
| 18790955 | ANTI-GPRC5D ANTIBODIES AND COMPOSITIONS | July 2024 | December 2024 | Allow | 4 | 0 | 1 | No | No |
| 18783156 | COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASS | July 2024 | June 2025 | Allow | 11 | 0 | 1 | Yes | No |
| 18780956 | HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION | July 2024 | September 2025 | Abandon | 13 | 2 | 0 | Yes | No |
| 18773461 | ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING | July 2024 | March 2025 | Allow | 8 | 1 | 1 | No | No |
| 18771877 | GRP78-BINDING ANTIBODIES AND USE THEREOF IN DETECTING OR NEUTRALIZING GRP78 | July 2024 | November 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18766845 | METHOD FOR TREATING SEPTIC SHOCK | July 2024 | March 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18750581 | METHODS FOR TREATMENT OF PSORIASIS WITH AN ANTI-OXLDL ANTIBODY | June 2024 | January 2026 | Allow | 19 | 1 | 0 | No | No |
| 18750971 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | June 2024 | September 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18746802 | Immunoconjugates | June 2024 | October 2025 | Allow | 16 | 0 | 1 | Yes | No |
| 18720291 | IL-4 DERIVED PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | June 2024 | April 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18739702 | NUCLEIC ACIDS ENCODING MODIFIED IMMUNOGLOBULIN FC REGIONS | June 2024 | August 2025 | Allow | 14 | 1 | 1 | No | No |
| 18737465 | BCG AND IL-15 BASED MOLECULES | June 2024 | March 2025 | Allow | 9 | 3 | 0 | No | No |
| 18737455 | IL-15-BASED MOLECULES WITH ANTI-CD20 ANTIBODY AND METHODS OF USE | June 2024 | February 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18733339 | ORTHOGONAL IL-21 RECEPTOR/CYTOKINE SYSTEMS | June 2024 | July 2025 | Allow | 13 | 1 | 1 | Yes | No |
| 18732612 | METHOD FOR PREVENTION OR TREATMENT OF DISEASES CAUSED BY PATHOGEN-ASSOCIATED MOLECULAR PATTERN | June 2024 | June 2025 | Abandon | 12 | 1 | 1 | No | No |
| 18680542 | METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST | May 2024 | September 2025 | Allow | 15 | 2 | 0 | Yes | No |
| 18678987 | METHOD FOR STIMULATING TUMOR-INFILTRATING LYMPHOCYTES WITH AN IL-15:IL-15R COMPLEX | May 2024 | October 2025 | Abandon | 17 | 3 | 0 | No | No |
| 18679187 | Advanced Avatar Dendritic Cells | May 2024 | October 2024 | Allow | 5 | 1 | 0 | No | No |
| 18671043 | ANTI-OX40 ANTIBODY AND METHOD OF TREATMENT | May 2024 | January 2026 | Allow | 19 | 1 | 0 | No | No |
| 18671707 | METHOD OF TREATMENT USING A BISPECIFIC ANTIBODY BINDING BCMA AND CD3 | May 2024 | July 2025 | Allow | 14 | 0 | 0 | Yes | No |
| 18671801 | TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN | May 2024 | October 2024 | Allow | 5 | 1 | 0 | No | No |
| 18656957 | HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION | May 2024 | April 2025 | Abandon | 11 | 1 | 1 | Yes | No |
| 18656236 | IL23R BINDING MOLECULES AND METHODS OF USE | May 2024 | March 2025 | Abandon | 10 | 0 | 1 | No | No |
| 18656092 | ANTI-SLC34A2 MONOCLONAL ANTIBODIES AND USES THEREOF | May 2024 | September 2024 | Allow | 5 | 0 | 1 | No | No |
| 18650566 | BIOPHARMACEUTICAL COMPOSITIONS | April 2024 | August 2024 | Allow | 4 | 0 | 1 | Yes | No |
| 18650552 | BIOPHARMACEUTICAL COMPOSITIONS | April 2024 | August 2024 | Allow | 4 | 0 | 1 | Yes | No |
| 18650526 | BIOPHARMACEUTICAL COMPOSITIONS | April 2024 | August 2024 | Allow | 4 | 0 | 1 | Yes | No |
| 18639678 | COMPOSITIONS COMPRISING IL-15N72D-BASED MOLECULES AND BACILLUS CALMETTE-GUERIN (BCG) | April 2024 | January 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18639659 | IL-15-BASED MOLECULES WITH IMMUNE CHECKPOINT INHIBITOR ANTIBODY | April 2024 | March 2026 | Abandon | 22 | 5 | 0 | Yes | No |
| 18634496 | FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | April 2024 | August 2025 | Allow | 16 | 2 | 1 | Yes | No |
| 18632662 | ANTI-TMEFF1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | April 2024 | July 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18630263 | CYTOKINE-BISPHOSPHONATE CONJUGATES | April 2024 | December 2024 | Allow | 8 | 1 | 0 | No | No |
| 18628440 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | April 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18626591 | Il-2 Mutant And Application Thereof | April 2024 | March 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18627131 | SCFV-FC DIMERS THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | April 2024 | July 2025 | Allow | 15 | 1 | 0 | Yes | No |
| 18615520 | NUCLEIC ACID MOLECULES ENCODING CLOSTRIDIUM HISTOLYTICUM COLLAGENASE I AND METHODS OF PRODUCING THE SAME | March 2024 | June 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18616055 | INTERLEUKIN-2 AGENTS AND USES THEREOF | March 2024 | September 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18612342 | Bispecific T cell Engagers | March 2024 | October 2025 | Allow | 18 | 2 | 1 | Yes | No |
| 18610618 | ANTI-GIANT PANDA LIF MONOCLONAL ANTIBODY, and HYBRIDOMA CELL LINE, AND USE THEREOF | March 2024 | November 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18611464 | IL-15-BASED FUSIONS TO IL-12 AND IL-18 | March 2024 | February 2025 | Abandon | 11 | 1 | 1 | Yes | No |
| 18604076 | THERAPEUTIC MOLECULES THAT BIND TO LAG3 AND PD1 | March 2024 | June 2025 | Abandon | 15 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1674.
With a 35.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Art Unit 1674 is part of Group 1670 in Technology Center 1600. This art unit has examined 6,233 patent applications in our dataset, with an overall allowance rate of 74.2%. Applications typically reach final disposition in approximately 27 months.
Art Unit 1674's allowance rate of 74.2% places it in the 42% percentile among all USPTO art units. This art unit has a below-average allowance rate compared to other art units.
Applications in Art Unit 1674 receive an average of 1.92 office actions before reaching final disposition (in the 52% percentile). The median prosecution time is 27 months (in the 68% percentile).
When prosecuting applications in this art unit, consider the following:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.